SCHEMBL15630779

SCHEMBL15630779

Cc1ccc(/C=C/C(=O)OC(C)(C)C)c(CO)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ NR1I2 O75469 1/20 0.41
▸ PGR P06401 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ ADORA3 P0DMS8 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ TBXAS1 P24557 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ CYP1A1 P04798 1/20 0.36
▸ CYP1B1 Q16678 1/20 0.36
▸ EGFR P00533 1/20 0.35
▸ ESR1 P03372 2/20 0.35
▸ PTGER1 P34995 2/20 0.35
▸ PTGER4 P35408 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15630822 0.89 EGFR (0.44) LMNAHTTNR1I2PGRCYP3A4
SCHEMBL15630782 0.88 LMNA (0.41) LMNAHTTNR1I2PGRCYP3A4
SCHEMBL15630818 0.85 LMNA (0.38) LMNAHTTNR1I2PGRCYP3A4
SCHEMBL12535832 0.82 CYP1A1 (0.51) LMNAHTTNR1I2PGRCYP3A4
SCHEMBL14110467 0.80 SRC (0.41) LMNAHTTNR1I2PGRCYP3A4
SCHEMBL15630827 0.80 LMNA (0.41) LMNAHTTNR1I2PGRCYP3A4
SCHEMBL15609816 0.79 EGFR (0.55) LMNAHTTCYP3A4CYP2C9CYP2C19
SCHEMBL15609817 0.79 EGFR (0.55) LMNAHTTCYP3A4CYP2C9CYP2C19
SCHEMBL15630821 0.78 EGFR (0.44) LMNAHTTNR1I2PGRCYP3A4
SCHEMBL15053698 0.75 LMNA (0.37) LMNAHTTNR1I2PGRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447090-B2 Imidazopyridine compounds ASTELLAS PHARMA INC. (JP) 2016-09-20 — — US disclosed
US-20140088080-A1 IMIDAZOPYRIDINE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2014-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088080-A1 IMIDAZOPYRIDINE COMPOUNDS GUCY1A1, PDE2A, GUCY1A2 LMNA 1848/4885HTT 4668/4885NR1I2 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback